GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188036 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Yuliy A Gorgul und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, 194223 Saint-Petersburg, Russia. Hauptthemen laut MEDLINE: Epilepsy, Glucagon-Like Peptide-1 Receptor Agonists, Neuroprotection, Neuroprotective Agents. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Ministry of Education and Science of the Russian Federation, Ministry of Science and Higher Education of the Russian Federation.
Abstract (Originalsprache)
GLP-1 receptor (GLP-1R) agonists are increasingly investigated in epilepsy, but antiseizure activity, neuroprotection, and disease modification are distinct therapeutic claims. This critical narrative review with structured evidence mapping separates these claims across 21 preclinical primary publications and eight human studies identified through 6 August 2026. Selected GLP-1R-related interventions show antiseizure and anti-kindling signals, but effects vary across compounds, models, treatment timing, and seizure types; null and pro-seizure findings in absence epilepsy preclude a uniform class-wide antiseizure effect, and concurrent anti-kindling does not establish antiepileptogenesis. Neuroprotective evidence is broader, although direct neuronal or tissue preservation is demonstrated only in selected studies; many findings remain biomarker-based, and seizure reduction may itself lessen downstream injury. Evidence for durable disease modification remains suggestive rather than established. Causal support is strongest at the receptor level, whereas most downstream synaptic, inflammatory, glial, oxidative, and mitochondrial evidence remains associative. Semaglutide has high translational relevance but remains directly under-tested in epilepsy, and human evidence is predominantly observational or safety-oriented and does not establish therapeutic epilepsy efficacy. Progress requires chronic epilepsy studies with longitudinal EEG/video-EEG and baseline seizure burden, post-insult designs controlling initial-insult severity and assessing persistence after withdrawal, and linked pharmacokinetic, target-engagement, and causal mechanistic testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, 194223 Saint-Petersburg, Russia.
ORCID-Profile: Yuliy A Gorgul, Aleksey V Zaitsev
Förderung
- The Ministry of Education and Science of the Russian Federation
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Gorgul, Y. A., & Zaitsev, A. V. (2026). GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188036
Vancouver
Gorgul YA, Zaitsev AV. GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188036
BibTeX
@article{Gorgul2026,
author = {Gorgul, Yuliy A and Zaitsev, Aleksey V},
title = {GLP-1 Receptor Agonists in Epilepsy: Separating Evidence for Antiseizure Activity, Neuroprotection, and Disease Modification},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188036}
}
EUVIMED